NorthSea Therapeutics B.V. , a newly established Dutch biotech company, announced the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of non-alcoholic steatohepatitis (‘NASH’).

Torque, an immuno-oncology company developing Deep Primed cell therapies that direct and evoke immune responses in the tumor microenvironment, announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering.

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series.

Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer.

Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel). 

Elsevier, the information analytics business specializing in science and health, has announced it is donating its Unified Data Model (UDM) to The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D.